Last updated: September 4, 2026
Infigratinib phosphate, marketed as Truseltiq, reached the U.S. market in 2021 as the first FDA-approved targeted therapy for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. Its commercial trajectory deteriorated because the eligible population was narrow, testing and treatment sequencing were complex, competing FGFR inhibitors entered the market, and the required confirmatory trial was difficult to enroll.
QED Therapeutics and Helsinn Healthcare announced the planned withdrawal of Truseltiq from the U.S. market. The FDA withdrawal became effective in May 2024. The withdrawal was commercial and development-related rather than a safety-driven recall. Truseltiq therefore has limited U.S. revenue potential, while residual value depends on international commercialization, clinical data, intellectual property, and potential use in selected FGFR-driven cancers.
What is infigratinib phosphate and how does it work?
Infigratinib phosphate is the phosphate salt of infigratinib, an orally administered selective tyrosine kinase inhibitor. It inhibits FGFR1, FGFR2 and FGFR3, with the principal commercial rationale centered on FGFR2 fusions and rearrangements in intrahepatic cholangiocarcinoma.
The drug was developed for tumors in which aberrant FGFR signaling drives proliferation and survival. The commercial product was supplied as oral capsules, with a standard treatment schedule of once-daily dosing for 21 consecutive days followed by seven days off treatment.
The U.S. label required selection of patients whose tumors had an FGFR2 fusion or rearrangement. This biomarker restriction materially reduced the addressable population compared with broader cholangiocarcinoma products.
What was the FDA regulatory status of Truseltiq?
The FDA granted accelerated approval to Truseltiq on May 28, 2021, under NDA 214622. The approved indication covered adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
The approval relied on overall response rate and duration of response from a single-arm clinical study. Under the accelerated approval framework, the sponsor was required to verify clinical benefit in a post-approval trial.
| Regulatory milestone |
Date or status |
| FDA accelerated approval |
May 28, 2021 |
| NDA |
214622 |
| Initial indication |
Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement |
| Approval basis |
Overall response rate and duration of response |
| Sponsor at approval |
QED Therapeutics, a BridgeBio Pharma company |
| Commercial partner |
Helsinn Healthcare for ex-U.S. markets |
| U.S. withdrawal |
Effective May 2024 |
| Withdrawal rationale |
Commercial and development considerations, not a safety recall |
The withdrawal removed the U.S. product from active commercial distribution but did not convert the historical approval into a successful full approval. The drug’s regulatory profile remains tied to an accelerated approval that did not generate a commercially sustainable confirmatory pathway.
When did infigratinib lose U.S. exclusivity?
Infigratinib lost practical U.S. exclusivity when commercial operations were discontinued and the FDA withdrawal became effective in May 2024. That commercial event occurred before the ordinary expiration of the drug’s listed patents.
The initial U.S. market protection also included regulatory exclusivity. Because Truseltiq received accelerated approval for an orphan oncology indication, it obtained orphan-drug exclusivity, which generally protects the approved indication for seven years from approval. The relevant orphan exclusivity period would have extended into 2028, subject to the effect of the withdrawal and FDA regulatory treatment.
FDA approval did not provide broad market exclusivity for all FGFR2-driven tumors. Protection was limited by the approved indication, biomarker requirement, patent scope, and the commercial availability of the product.
What patents protect infigratinib phosphate?
Truseltiq’s patent protection is based primarily on patents covering the infigratinib chemical entity, pharmaceutical compositions, and therapeutic use. Public patent records and FDA listing data identify issued U.S. patents associated with the product, including patents in the US10.6 million and US10.8 million series. Patent expiry dates extend into the mid-2030s for at least some U.S. rights, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable disclaimers or legal amendments.
The principal protection categories are:
| Protection category |
Commercial relevance |
| Active pharmaceutical ingredient |
Restricts production and sale of infigratinib itself |
| Pharmaceutical composition |
May cover the active ingredient in specified formulations or dosage forms |
| Treatment methods |
May cover use in FGFR-driven tumors or biomarker-defined patients |
| Salt and solid-state forms |
Can restrict selected manufacturing routes and product presentations |
| Manufacturing processes |
May raise process-development and scale-up barriers |
| Regulatory exclusivity |
Protects the approved orphan indication for a defined period |
The commercial value of these patents is now lower than it would have been during an active U.S. launch. Patent duration alone does not create market value where the reference product has been withdrawn and the treated population is narrow.
How strong is the infigratinib patent estate?
The estate is technically meaningful but commercially weakened. Composition-of-matter claims generally provide the strongest protection because they can block competing products using the same active ingredient. Method-of-use claims are narrower and more exposed to design-around strategies, especially where competitors can target the same disease with different FGFR inhibitors.
The estate has four practical limitations:
- The indication is biomarker-defined and relatively small.
- The product no longer has an active U.S. commercial platform.
- Competitors can pursue different molecules against FGFR2.
- Generic entry litigation is less attractive when the reference product has limited or no current U.S. sales.
The patent estate may retain value in licensing, international commercialization, or combination studies, but it has limited ability to restore the former U.S. revenue model.
How did infigratinib’s financial trajectory develop?
Infigratinib had a launch profile characterized by early uptake followed by commercial pressure rather than sustained expansion. The main constraints were the small FGFR2-positive cholangiocarcinoma population, treatment-line restriction, molecular testing requirements, physician familiarity with alternative regimens, and the need to manage class-related toxicities.
Public company reporting did not establish a durable, independently reported blockbuster revenue stream for Truseltiq. BridgeBio and QED disclosures described the product as a commercial asset, but the company later concluded that the U.S. market and development economics did not justify continued commercial investment.
Financial trajectory
| Period |
Financial interpretation |
| 2021 launch |
Initial revenue generation after accelerated FDA approval |
| 2022 |
Expansion depended on molecular testing, treatment adoption and international rollout |
| 2023 |
Revenue potential remained constrained by competition and narrow indication |
| 2024 |
U.S. withdrawal eliminated the principal commercial growth opportunity |
| Post-2024 |
Value shifted from U.S. product sales to international rights, licensing and residual IP |
The withdrawal indicates that commercial performance did not support continued U.S. infrastructure, confirmatory development and market access costs. The economics were affected by the difference between a clinically responsive niche and a sufficiently large reimbursed market.
What caused the commercial decline of Truseltiq?
The commercial decline resulted from multiple market factors rather than a single clinical failure.
Narrow biomarker-defined market
FGFR2 fusions and rearrangements occur in a minority of intrahepatic cholangiocarcinoma patients. Testing is required before treatment, and not all eligible patients are identified early enough to receive a targeted therapy.
Later-line treatment positioning
Truseltiq was approved for previously treated disease. Patients in later lines often have deteriorating performance status, shorter treatment duration and limited ability to tolerate targeted therapy. A later-line label also reduces the number of patients who reach treatment.
Competitive pressure
Pemigatinib, marketed as Pemazyre, was approved for a similar FGFR2-altered cholangiocarcinoma population before or near the time of infigratinib’s launch. Futibatinib, marketed as Lytgobi, later added another FGFR-directed option for previously treated intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements.
The resulting market had several targeted products competing for a small population. Competition affected physician choice, contracting, patient access and clinical-trial enrollment.
Toxicity and monitoring burden
FGFR inhibitors require management of hyperphosphatemia, ocular toxicity, nail and skin effects, stomatitis and other adverse events. These monitoring requirements increase treatment friction and may favor products with differentiated dosing, safety or efficacy profiles.
Confirmatory trial risk
The accelerated approval pathway required evidence of clinical benefit after approval. Difficulty enrolling a confirmatory trial reduced the probability of converting the accelerated approval into a durable full approval and weakened the commercial case for continued investment.
How does infigratinib compare with competing FGFR inhibitors?
| Drug |
Active ingredient |
Sponsor or marketer |
Principal cholangiocarcinoma positioning |
Commercial status |
| Truseltiq |
Infigratinib phosphate |
QED Therapeutics and Helsinn |
Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma |
U.S. withdrawal effective 2024 |
| Pemazyre |
Pemigatinib |
Incyte |
FGFR2 fusion or rearrangement-positive cholangiocarcinoma |
Active commercial competitor |
| Lytgobi |
Futibatinib |
Taiho Oncology |
Previously treated intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements |
Active commercial competitor |
Infigratinib’s differentiation included early clinical validation, oral administration and selectivity for the FGFR pathway. Those attributes were insufficient to overcome the disadvantage of a narrow later-line market and a less favorable commercial trajectory.
What is the Orange Book status of infigratinib?
Truseltiq was approved under NDA 214622 and associated U.S. patent information was submitted for FDA listing. The commercial relevance of Orange Book-listed patents declined after the withdrawal of the product.
An Orange Book listing can support a patent certification dispute if a generic applicant submits an abbreviated new drug application. A Paragraph IV certification would assert that a listed patent is invalid, unenforceable or not infringed. Infigratinib’s U.S. withdrawal makes that pathway less commercially attractive because a generic applicant would face uncertain demand and a limited reference-product market.
A Paragraph IV challenge could still arise if:
- a generic company expects use of infigratinib outside the withdrawn indication;
- the FDA permits or maintains a viable generic approval pathway;
- a generic applicant seeks to enter before relevant patents expire;
- a partner intends to relaunch or maintain the product through a new commercial structure.
No major public Paragraph IV litigation became a defining part of Truseltiq’s commercial history before the U.S. withdrawal.
What generic entry risks exist for infigratinib?
Generic entry risk is technically present but economically muted. Composition-of-matter and formulation patents may delay approval, while method-of-use patents may be vulnerable to skinny-label or carve-out strategies. A generic company would also need to assess bioequivalence, product supply, restricted market demand and the status of the reference NDA after withdrawal.
The most likely entry scenarios are:
- No immediate generic launch because the U.S. market is commercially unattractive.
- A patent challenge tied to a relaunch or retained orphan market.
- International generic entry after local patent expiry or where patent protection is weak.
- A future approval for a different FGFR-related indication, if supported by clinical data.
What litigation and settlement agreements affect infigratinib?
No major publicly reported patent settlement shaped the U.S. infigratinib market before withdrawal. The more important legal event was the regulatory and commercial decision to discontinue U.S. operations.
The main legal risks now concern:
- validity and enforceability of listed patents;
- ownership and licensing rights between BridgeBio, QED and Helsinn;
- post-withdrawal supply and patient access;
- international commercialization rights;
- clinical-trial obligations linked to accelerated approval;
- potential relaunch or transfer of commercialization rights.
What licensing deals cover infigratinib?
QED retained responsibility for development and U.S. commercialization, while Helsinn obtained rights for markets outside the United States. The partnership was designed to combine QED’s FGFR program with Helsinn’s international commercial infrastructure.
The arrangement created potential value in Europe and other territories, but international rights did not eliminate the underlying market constraints. The addressable population remained biomarker-defined, and competing FGFR inhibitors were available or under development in several jurisdictions.
The principal licensing question is whether international sales can support manufacturing, regulatory maintenance and post-approval obligations after U.S. withdrawal. The answer depends on regional reimbursement, local competition and the size of the FGFR2-positive patient pool.
What is the outlook for infigratinib phosphate?
The U.S. outlook is limited. The product has no active growth trajectory comparable to a continuing specialty oncology launch because the FDA withdrawal removed the core U.S. commercial channel.
Residual value may persist in four areas:
- international sales through Helsinn or successor arrangements;
- licensing of the molecule or patent estate;
- investigator-sponsored studies in additional FGFR-altered tumors;
- manufacturing or formulation know-how that can support a strategic transaction.
A material value recovery would require a new clinical or commercial rationale, such as a differentiated combination regimen, a broader biomarker-defined indication, improved treatment sequencing or a regional relaunch. The historical U.S. indication alone is unlikely to support substantial revenue growth.
Key Takeaways
- Infigratinib phosphate is the active ingredient in Truseltiq, an oral FGFR inhibitor.
- The FDA granted accelerated approval in May 2021 for previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma.
- The product competed with pemigatinib and futibatinib in a narrow biomarker-defined market.
- U.S. commercial operations were discontinued, and FDA withdrawal became effective in May 2024.
- The withdrawal was not a safety recall.
- Patent protection extends into the mid-2030s for certain U.S. rights, but patent duration has limited commercial value after withdrawal.
- No major Paragraph IV litigation or patent settlement defined the U.S. market.
- Future value depends mainly on international rights, licensing, residual IP and potential new clinical development.
FAQs
Is infigratinib phosphate still FDA approved?
The original Truseltiq approval was withdrawn in the United States, with the withdrawal effective in May 2024. The product is therefore not an active U.S. commercial growth asset.
Is Truseltiq the same as infigratinib?
Yes. Truseltiq is the branded product containing infigratinib phosphate.
Which company owns infigratinib?
QED Therapeutics, a BridgeBio Pharma company, developed and commercialized the U.S. product. Helsinn held rights for markets outside the United States under a commercialization agreement.
Is infigratinib a biosimilar risk?
No. Infigratinib is a small-molecule drug, not a biologic. Follow-on competition would proceed through the generic drug pathway rather than the FDA biosimilar pathway.
Could infigratinib return to the U.S. market?
A return would require a new commercial strategy and a viable regulatory basis. Potential routes could include a relaunch, transfer to another sponsor or development for a new indication, but the withdrawn U.S. market does not support a straightforward continuation of the original business model.
References
- U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024). Drug safety and availability: Truseltiq withdrawal information. https://www.fda.gov
- BridgeBio Pharma, Inc. (2024). Annual report on Form 10-K. https://ir.bridgebio.com
- Helsinn Healthcare SA. (2021). Helsinn and QED Therapeutics announce licensing agreement for infigratinib outside the United States. https://www.helsinn.com
- U.S. Food and Drug Administration. (2022). Pemazyre prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2022). Lytgobi prescribing information. https://www.accessdata.fda.gov
